Salute e Benessere

3Shape Unveils Revolutionary TRIOS 6 Intraoral Scanner and TRIOS Dx Plus…

3Shape CEO Jacob Paulsen, says, "As transformative as our launch of the world's first wireless intraoral scanner was back in 2017, the new TRIOS 6, together with TRIOS Dx Plus software and the DentalHealth app, will revolutionize the way dentists work." 3Shape CEO Jacob Paulsen, says, "As transformative as our launch of the world's first wireless intraoral scanner was back in 2017, the new TRIOS 6, together with TRIOS Dx Plus software and the DentalHealth app, will revolutionize…

Rare loss-of-function variants in HECTD2 and AKAP11 confer a risk of bipolar…

Significant progress has occurred over the last 15 years through genome-wide association studies leading to the identification of hundreds of biomarkers, i.e. DNA sequence variants, associated with the risk of psychiatric disease, including bipolar disorder. These biomarkers represent common variations each carrying a small risk, but in confluence, they are beginning to account for a considerable part of the variance in psychiatric traits and disorders. Variants predicted to cause loss of…

TFS HealthScience Appoints Miriam Martin as Vice President of Business…

"Miriam's impact on TFS is both profound and enduring," said Markus Granlund, CEO of TFS HealthScience. "She has played an integral role in shaping the TFS we know today. Her leadership, insight, and unwavering commitment to our company and mission make her the ideal person for this role. We are proud to welcome her to the Executive Committee." "Miriam's impact on TFS is both profound and enduring," said Markus Granlund , CEO of TFS HealthScience. "She has…

Nature's Best reveal the simple fix for 4 million who struggle with tablets

Findings revealed that 32% reported difficulty when swallowing tablets or capsules whole. In comparison, 55% had previously experienced difficulties at some point in their lives. Findings revealed that 32% reported difficulty when swallowing tablets or capsules whole. In comparison, 55% had previously experienced difficulties at some point in their lives. In addition, the study highlighted that consumers are unlikely to seek advice from a healthcare professional before splitting or crushing...

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight…

Speaking at the launch, Hon. Josephine I. Iquina, Municipal Mayor, Malinao said, "The fight against malnutrition requires a collective effort, and we appreciate Glenmark's commitment to improving nutrition and health outcomes in vulnerable communities. This initiative is a vital step in ensuring that mothers and children receive the nutrition they need while strengthening local capacity for long-term impact. By working with partners like Health Futures Foundation and the local government…

RevitaLash® Cosmetics Partners with Future Dreams and the Francis Crick…

The partnership furthers the impact of RevitaLash® Cosmetics' Eternally Pink® pledge to support the fight against breast cancer in honour of the brand's co-Founder, Gayle Brinkenhoff's legacy. With more than $9 million in donations, investments, and in-kind contributions to breast cancer initiatives worldwide since 2008, RevitaLash® Cosmetics aims to reach a new milestone in 2025 through their Road to $10 Million philanthropic goal, of which this project is a part. The partnership furthers…

Philips demonstrates innovation power, topping European Patent Office Medtech…

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that in 2024 it was the leading applicant in the field of medical technology at theEuropean Patent Office(EPO), filing 594 Medtech patent applications. This achievement underscores the company's ongoing dedication to transforming healthcare delivery by integrating informatics and AI to improve workflows, enhance the quality of care, and lower costs of care per...

Implantica's RefluxStop™ garners strong interest at SAGES

Independent surgeons from Switzerland and Austria shared their real-world experience with RefluxStop™ and clinical outcomes in three presentations and a poster. These exciting educational sessions were filled with lively discussion as the strong outcomes data from Europe were presented, and the unique mechanism of action of RefluxStop™ was discussed with interest and excitement. Independent surgeons fromSwitzerlandandAustriashared their real-world experience with RefluxStop ™ and...

AMBOSS closes €240M financing round and expands its position as the leading…

"We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond," commented Benedikt Hochkirchen, Co-Founder and Co-CEO of AMBOSS. "Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy." In 2024, AMBOSS acquired Novaheal, a…

BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual…

--- --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, onMarch 25, 2025, at07:50 AM CET. For further information, please contact: Oskar Bosson, VP Communications and IR E-mail: [email protected]: +46 70 410 71 80 Charlotte af Klercker, Senior Director Sustainability and...

Medit Launches Medit i900 classic, a New Addition to Medit i900 Family Line Up

The Medit i900 classic introduces several enhancements designed to improve both efficiency and ease of use: The Mediti 900 classic introduces several enhancements designed to improve both efficiency and ease of use: Enhanced Benefits for Every Dental Professional The Mediti 900 classic is crafted to enhance the experience for clinicians, labs, and patients by ensuring seamless communication, high-quality scanning, and workflow efficiency. The Mediti 900 classic continues...

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the…

Press ReleaseCROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency programCROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON's net sales. ETON confirmed its commitment to finalize the development and...

Novartis to present new data at AAN, including seven-year disability outcomes…

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presentedAdditional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for...

Press Release: Tolebrutinib regulatory submission accepted for priority review…

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosisIf approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was...

NMD Pharma presents preclinical data highlighting increased innervation of…

Company presented clinical and preclinical data at the MDA Conference last week in Dallas, TexasOral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the structural integrity of the neuromuscular junction and innervation of skeletal muscle Other poster presentations included data from Phase 2a clinical study in myasthenia gravis and status updates for the three ongoing Phase 2 trials with its novel, oral,...

Valneva Announces Filing of 2024 Universal Registration Document and US Form…

Saint-Herblain (France), March 25, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).Valneva's 2024 Universal Registration Document – available in its entirety in French – includes the Company's 2024...

XRP Healthcare to Become Public Company via IPO by Q3 2025, Accelerating AI and…

The company today confirmed it is accelerating its initial public offering (IPO) timeline, moving the planned listing date from 2027 to the third quarter of this year on a Canadian stock exchange. This bold move is designed to fast-track the company's expansion strategy, unlock new investment opportunities, and cement its position as a global leader in healthcare transformation. This decision follows a series of high-impact developments, including the acquisition of Pharma Ville, a...

Exceptional Performance for Ureteral Stents: ICP DAS-BMP Reveals Latest TPU…

Complementing this highlight are other groundbreaking TPU solutions. The Arothane™ ARP-W-G series, contained with 40-60% Tungsten, provides excellent radiopacity for thin-walled medical devices and reliable performance for guidewire coatings. Additionally, the Arothane™ ARP-B20 and Durathane™ ALC-B40, enhanced with Barium Sulfate, deliver certified safety for extended implantation. Complementing this highlight are other groundbreaking TPU solutions. The Arothane™ ARP-W-G series, contained…

HUMAN AFTER ALL: THE ALTERNATIVE TEAM PHOTO EXPOSES THE PERSONAL SIDE OF NEW…

Uniting past and present athletes from the internationally-renowned All Blacks, All Black Sevens, Black Ferns and Black Ferns Sevens, the campaign follows global research from Bupa revealing that 71% of young adults (18–44 year-olds) believe role models can inspire positive health change. Uniting past and present athletes from the internationally-renowned All Blacks, All Black Sevens, Black Ferns and Black Ferns Sevens, the campaign follows global research from Bupa revealing that 71% of…

Spring Clean Smarter with Dreame: Enjoy Up to 25% Off in Our Biggest Sale of the…

X50 Ultra Complete: Rise Up, Clean Beneath X50 Ultra Complete: Rise Up, Clean Beneath Available onAmazon& the Dreame Store Dreame's most advanced robot vacuum, the X50 Ultra Complete, introduces a new level of home cleaning with its ProLeap™ System featuring 6cm obstacle-crossing ability. Its VersaLift Navigation allows the robot to lower itself to just 8.9cm for deep cleaning under furniture. The HyperStream™ Detangling DuoBrush System effectively captures and removes hair,...

In-Licensing Opportunity: How a Pharma Leader Leveraged Scientific Innovation…

Recognizing the situation's complexity and the advantages of in-licensing and out-licensing, the company turned to DelveInsight, a trusted expert in pharma market intelligence and strategic licensing. Using a combination of secondary and primary intelligence, DelveInsight conducted a deep dive into the pharma in-licensing landscape, identifying the most promising players in the microneedle technology space. The assessment provided the company with a clear roadmap—pinpointing potential partners…

CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies…

Janssen's CARVYKTI (ciltacabtagene autoleucel) Overview Janssen's CARVYKTI (ciltacabtagene autoleucel) Overview CARVYKTI is an autologous T-cell immunotherapy that targets B-cell maturation antigen (BCMA). It works by genetically modifying a patient's T cells with a transgene that encodes a chimeric antigen receptor (CAR). This CAR helps the T cells recognize and destroy cells expressing BCMA, which is primarily found in malignant multiple myeloma B-lineage cells, late-stage B cells, and...

Natural Cosmetics Market Projected to Reach $35.96 Billion by 2032, Growing at…

Market Drivers and Emerging Trends Market Drivers and Emerging Trends The natural cosmetics industry is experiencing unprecedented growth, propelled by increasing consumer awareness regarding potentially harmful synthetic ingredients. This shift is characterized by growing preference for organic and plant-based formulations, alongside stricter regulatory frameworks promoting environmentally friendly products. Digital platforms and social media have significantly amplified this trend, with...

SKIMS ACQUIRES SKKN BY KIM FROM KIM KARDASHIAN AND COTY, BRINGING KARDASHIAN'S…

Kardashian's beauty legacy is undeniable. Her 2017 launch of KKW Beauty sparked a contouring revolution, while KKW Fragrance won "Fragrance of the Year" at the 2020 FiFi Awards. SKKN by Kim further elevated her influence, blending minimalist luxury with science-driven skincare. Kardashian's beauty legacy is undeniable. Her 2017 launch of KKW Beauty sparked a contouring revolution, while KKW Fragrance won "Fragrance of the Year" at the 2020 FiFi Awards. SKKN by Kim further…

Altri Comunicati